Therapeutics News

With the impending availability of a vaccine for COVID-19, the American Optometric Association is advocating for optometrists to be involved the vaccination process.

Lumify and Besivance showed complete inactivation of COVID-19 in an investigational study, researchers reported at the Ocular Microbiology and Immunology Group annual meeting.

Choroidal thickness decreased in patients with diabetic macular edema after five intravitreal injections of anti-VEGF, according to a study published in the Journal of Ophthalmology.

Results from a phase 2b study of a pilocarpine and oxymetazoline combined topical eye drop for the treatment of presbyopia significantly improved uncorrected near visual acuity.

Pooled analysis showed that KPI-121 0.25% from Kala Pharmaceuticals, a nanoparticle suspension of loteprednol etabonate with proprietary mucus-penetrating particle technology for dry eye treatment, was safe and well-tolerated.

A 24-year-old white man presented with a chief complaint of a suspected metallic foreign body in his right eye. The patient stated he was cutting a metal band earlier that day.

We have seen an incredible diversity of advances in dry eye therapy over the last decade. As we add more treatment options, we can vastly improve the ability to manage this inflammatory disease and enhance patients’ vision and comfort.

Eyenovia reported successful clinical trial results for three different ocular pharmaceutical solutions delivered with its Optejet microdose dispenser for mydriasis, myopia and presbyopia.

Novartis plans further clinical development of UNR844, a topical ophthalmic solution for treating presbyopia, based on results of phase 1 and 2 studies, according to a presenter here at the American Academy of Optometry virtual meeting.

Despite stalls in development due to COVID-19, eye care providers can look forward to new treatments for ocular surface disease. As our understanding of the disease and its underlying mechanisms broadens, so does the industry's response.